BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Boehringer Ingelheim48 enrolled

Overview

The purpose is to investigate the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics and efficacy of BI 836826 monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma with at least prior treatments.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma, Non-Hodgkin

Interventions

BI 836826DRUG

Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: 1. Patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin (mature B cell lymphoma according to WHO) not considered candidates for intensive anti-lymphoma therapy 2. Patients must have either aggressive NHL and received at least one prior anti-CD20 containing immunochemotherapy or indolent NHL and received anti-CD20 therapy and at least two prior therapies 3. Measurable disease on computed tomography (CT) scan with involvement of one clearly demarcated lesion =2 cm or two or more clearly demarcated lesions of \>1.5 cm at longest diameter (this criterion applies only for the expansion cohort) 4. Relapse or progression of disease with an indication for therapy as per investigator's judgement 5. Life expectancy of =3 months 6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Exclusion criteria: 1. Primary central nervous system (CNS) lymphoma or known CNS involvement 2. Prior history of malignancy other than a mature B cell neoplasm according to WHO classification (except basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the uterine cervix or breast treated with curative therapy) unless the subject has been free of disease and without treatment for at least 5 years 3. Last chemotherapy \<4 weeks prior to visit 1 4. Last anti-CD20 therapy (non-radiolabelled) \<4 weeks prior to visit 1 5. Last corticosteroid \<2 weeks prior to visit 1 unless the dose is less or equal of 10 mg/day prednisolone or equivalent 6. High-dose therapy with stem cell support \<6 months prior to visit 1 7. Radio-immunotherapy \<3 months prior to visit 1

Locations (12)

INS Paoli-Calmettes

Marseille, France

HOP Lyon Sud

Pierre-Bénite, France

Charité - Universitätsmedizin Berlin

Berlin, Germany

Outcomes

Primary Outcomes

Determination of the Maximum Tolerated Dose (MTD) Based on the Occurrence of Dose-limiting Toxicity (DLT) in First Cycle in Caucasian Patients

The primary objective of the dose-escalation part of this study was to determine the MTD of BI 836826 in caucasian patients. The MTD was to be defined on the basis of DLTs observed during the first 2 weeks of the 1st treatment course. In case of a delay of the second administration, evaluation of DLT was to be prolonged to 7 days after the second administration.. A DLT was defined as any drug-related non-haematological Adverse event (AE) of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or higher, except Infusion-related reaction (IRRs) associated with the administration of BI 836826.

Time frame: From the first administration of trial medication to 7 days after the second administration, upto 36 days

Number of Subjects With Dose Limiting Toxicities (DLT) in First Cycle in Caucasian Patients

Number of subjects with Dose Limiting Toxicities (DLT) in first Cycle during the MTD evaluation period in caucasian patients with relapsed or refractory Non-Hodgkin lymphoma (NHL).

Time frame: From the first administration of trial medication to 7 days after the second administration, up to 36 days

Secondary Outcomes

Tumour Size Reduction

Tumour size reduction (lymph nodes, spleen, \& liver nodules) defined as best percentage change from baseline in sum of products of diameter (SPD). Negative value represents decrease in tumour size, \& positive value represents an increase in size. The tumour size of lymph nodes was to be measured as SPD of 2 perpendicular dimensions for up to 6 indicator lesions identified at baseline CT scan. Spleen \& liver were to be described if considered enlarged at baseline by physical examination or CT scan. If nodules present in spleen \&/or liver, was to be measured in 2 perpendicular dimensions. Median, 25th \& 75th percentiles are calculated from unadjusted Kaplan-Meier curve for each treatment cohort.

Time frame: Computed tomography (CT) scan performed at screening, at Week 13, and at Week 25.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Universitätsklinikum Carl Gustav Carus Dresden

Dresden, Germany

Universitätsklinikum Frankfurt

Frankfurt am Main, Germany

Universitätsmedizin Göttingen, Georg-August-Universität

Göttingen, Germany

Asklepios Klinik St. Georg

Hamburg, Germany

Universitätsklinikum Heidelberg

Heidelberg, Germany

Universitätsklinikum Jena

Jena, Germany

Universitätsklinikum Ulm

Ulm, Germany

...and 2 more locations

Best Overall Response Based on All Assessment

Best overall response was best response at any of CT scans and investigator assesment (incase the recent CT scan was not available). Response was assessed as follow according to the Standardized or Revised Response Criteria for Malignant Lymphoma from 1999.: 1. Complete remission (CR) 2. Complete remission unconfirmed (CRu) 3. Partial remission (PR) 4. Stable disease (SD) 5. progressive disease (PD)

Time frame: Screening, Week 1, Week 4, Week 7, Week 8, Week 11, Week 14, Week 15, Week 18 and at End of Treatment (EOT)

Best Overall Response Based on Imaging Data

Best overall response based on imaging data. Response was assessed as follow according to the Standardized or Revised Response Criteria for Malignant Lymphoma from 1999.: 1. Complete remission 2. Complete remission unconfirmed 3. Partial remission 4. Stable disease: 5. progressive disease

Time frame: Computed tomography (CT) scan performed at screening, at Week 13, and at Week 25.

Progression Free Survival (PFS)

PFS was defined as the time from first treatment with BI 836826 until disease progression or death from any cause. For disease progression one of the following criteria was required: • Any new lesion \>1.5 centimeter (cm) in any axis • Increase of ≥50% from nadir in sum of product of diameter of any previously involved nodes or single nodes or the size of hepatic or splenic nodules. A lymph node with a diameter of the short axis of \<1 cm had to increase by ≥50% and to a size of 1.5 x 1.5 cm or more than 1.5 cm in the long axis • Increase of ≥50% in the longest diameter of any single previously identified node \>1 cm in its short axis. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment cohort.

Time frame: from first treatment until disease progression or death from any cause, up to 12 months.

Failure Free Survival (FFS)

FFS was defined as the time from first treatment with BI 836826 until objective disease progression, death, or start of next Non-Hodgkin lymphoma (NHL) therapy.For disease progression one of the following criteria was required: • Any new lesion \>1.5 centimeter (cm) in any axis • Increase of ≥50% from nadir in sum of product of diameter of any previously involved nodes or single nodes or the size of hepatic or splenic nodules. A lymph node with a diameter of the short axis of \<1 cm had to increase by ≥50% and to a size of 1.5 x 1.5 cm or more than 1.5 cm in the long axis • Increase of ≥50% in the longest diameter of any single previously identified node \>1 cm in its short axis. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment cohort.

Time frame: from first treatment with BI 836826 until objective disease progression, death, or start of next NHL therapy, up to 12 months.